Gamma Oryzanol for Health & Longevity - Quick Reference Sheet

Gamma Oryzanol for Health & Longevity

Created on 10/17/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 4 Argon – Audit

Gamma oryzanol is a rice bran dietary supplement and Japanese oral medication for cholesterol, blood sugar, menopausal comfort, mood, and strength. Every human benefit carries Low evidence; antioxidant, liver, and anticancer effects are Speculative. Fortified oils and hormone combinations drive metabolic and menopausal gains, while oral capsules rarely beat placebo outside untrained strength. Adverse events match placebo, though thyroid-stimulating hormone suppression requires paired free thyroid hormone testing. (Full Review)

Protocol

Lipid and cardiometabolic protocol
300 mg/day orally or 300–800 mg/day in oil
100 mg orally three times daily, or 30 g/day enriched oil for dyslipidemia and diabetes
Autonomic and menopausal protocol
10–50 mg 3×/day or 300 mg/day orally
90–300 mg/day for menopausal support; 500–600 mg/day for strength; 100 mg/day in older adults
Optimal time of day
Immediately after breakfast, lunch, and dinner
Split into three 100 mg doses with fat-containing meals (5–7 h half-life); 100 mg/day with dinner for sleep
Time to effect
LDL-C, HbA1c, hs-CRP, and strength gains
4–16 weeks
Blood markers reassessed at 8–12 weeks; lipid regimens run 16–52 weeks
Autonomic and mood improvements
2–8 weeks
Autonomic and mood improvements appear in 2–8 weeks; reassessed at 4–12 weeks
Skin hydration
8–12 weeks
Stratum corneum water content increases at weeks 8 and 12 with enriched rice bran oil

Benefits

Contraindications
  • Known hypersensitivity to gamma-oryzanol or rice (Oryza sativa) bran derivatives
  • Pregnant and lactating women
  • Patients with active hepatic disease or biliary tract obstruction
  • Patients with untreated or unstable primary hypothyroidism (unsupervised doses ≥300 mg/day)
Key Interactions
  • Cytochrome P450 substrates (midazolam, warfarin, omeprazole, dextromethorphan, caffeine) (theoretical)
  • Thyroid medications (levothyroxine, liothyronine, methimazole) (300 mg daily)
  • Prescription lipid-lowering agents (atorvastatin, rosuvastatin, ezetimibe, cholestyramine) (theoretical)
  • Antidiabetic medications (metformin, glimepiride, insulin glargine) (theoretical)
  • Menopausal hormone therapy (estradiol, dydrogesterone, conjugated estrogens) (90 mg daily)
  • Over-the-counter sedating antihistamines and sleep aids (diphenhydramine, doxylamine) (theoretical)
  • Lipid- and glucose-lowering supplements (phytosterols, red yeast rice, berberine) (theoretical)
  • High-intensity endurance and resistance training (theoretical)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Thyroid-stimulating hormone suppression; mild gastrointestinal disturbances; central nervous system symptoms; cutaneous hypersensitivity and flushing
  • Speculative: Gonadotropin and growth hormone suppression; hepatic transaminase elevation; blunting of exercise-induced hormetic adaptations

Monitoring

Marker Target Why
LDL-C No established target; tracks ≥8%–12% reduction from individual baseline Efficacy marker: primary atherogenic lipid fraction expected to decrease with gamma-oryzanol or enriched rice bran oil.
Fasting Glucose & HbA1c Fasting glucose 70–99 mg/dL; HbA1c 4.0%–5.6% (standard reference range) Efficacy marker: evaluates glycemic response to gamma-oryzanol interventions in insulin-resistant or diabetic adults.
hs-CRP No established target; tracks reduction from individual baseline Efficacy marker: tracks reductions in low-grade systemic inflammation observed with gamma-oryzanol-fortified oil.
TSH & Free T4 TSH 0.4–4.5 mIU/L; Free T4 0.8–1.8 ng/dL (standard reference range) Safety check: detects hypothalamic-pituitary TSH suppression at doses ≥300 mg/day that alters thyroid management.
ALT & AST ALT 7–56 U/L; AST 8–33 U/L (standard reference range) Safety check: screens for rare idiosyncratic hepatic transaminase elevations noted in pharmaceutical labeling.

Cadence: Baseline prior to initiation; recheck TSH and free T4 at 4–6 weeks (when taking ≥300 mg/day or thyroid hormone replacement); reassess lipid, glycemic, inflammatory, and hepatic markers at 8–12 weeks; repeat every 6 months during maintenance.

Qualitative Assessment

  • Vasomotor comfort: Weekly frequency of hot flashes and digestive complaints.
  • Sleep and mood: Subjective sleep continuity and daytime depressive or agitation symptoms.
  • Strength progression: Logbook tracking of 1-RM lifts in novices.